

Value of inhaled treatment with aztreonam lysine in bronchiectasis







All Visits

Participant Transport

Participants should be offered a taxi to bring them to the appointment and return them home. This has been proven to help recruitment and retention of trial participants.

- An account should be set up with a local taxi company for this as per local practice.
- Alternatively, participants wishing to use public transport should have their cost reimbursed or petrol paid. This should be done as per local procedure e.g. from petty cash or by completing a travel expense form.

Participant Identity

Participant identity should be checked at each visit. Some examples of identification are listed below:

- Current Passport
- Current photographic driving licence
- Current matriculation card
- Young person's or senior citizen's railcard
- Proof of Address
- National Insurance Card
- CHI Number/Medical Card





Participant trial ID

All participants consented to the trial should be allocated a participant ID number.

Participant ID numbers are made up of four numbers:

- First two numbers to indicate the site and
- Last two indicate the participant number at that site. e.g. 01-001 is the first participant at site one.
- Use participant ID numbers in order
- ensure site ID is correct for your site.

If participant fails screening, and does not go on to randomisation, their participant ID number should not be re-used.

Worksheets

Worksheets will be provided to facilitate data collection

Their use is not mandatory

If worksheets are used to record source data, they must be filed in the medical notes.









All Visits Trial Matrix

Index Math 1 Mark 1 </th <th>Type of visit</th> <th>Screening V1</th> <th>Baseline and randomization V2</th> <th>Follow-up phone call V3</th> <th>Follow-up phone call V4</th> <th>Follow-Up Assessments V5</th> <th>Final visit Assessments V6</th> <th>Unscheduled visit Assessments</th>	Type of visit	Screening V1	Baseline and randomization V2	Follow-up phone call V3	Follow-up phone call V4	Follow-Up Assessments V5	Final visit Assessments V6	Unscheduled visit Assessments
Inclusion Chines OncolsxxxxxxxxxxRecord Concordiant MetricitorsxxxxxxxxxxProjecal EcontributionxxxxxxxxxxProjecal EcontributionxenergyenergyxenergyxxxxxProjecal EcontributionxenergyenergyenergyenergyenergyenergyenergyenergyProjecal EcontributionxenergyenergyenergyenergyenergyenergyenergyenergyProjecal EcontributionxenergyenergyenergyenergyenergyenergyenergyCheck Vial Signs'xenergyenergyenergyenergyenergyenergyenergyCheck Vial Signs'xenergyenergyenergyenergyenergyenergyenergyCheck Vial Signs'xenergyenergyenergyenergyenergyenergyenergyUna and electrobicsxenergyenergyxenergyenergyenergyenergySpalan Signels For CS-S and BiblioxxxxxxxxxSpalan Signels For CS-S and BiblioxxxxxxxxxSpalan Signels For CS-S and Biblioxxx<	Timeline	Month -1 to 0	Up to 35 days after screening	(4 weeks)	(12 weeks)	(24 weeks)	(48 weeks)	As Required
MediaNetworkNNNNNNNNNPhysical DarinationXXXXXXXXPhysical DarinationXNNNNNNNPhysical DarinationXNNNNNNNNWeightXNNNNNNNNNNNCheck Vial Syste*XNN <td< td=""><td>Informed Consent</td><td>Х</td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	Informed Consent	Х						
Record concreted MeticalionsXXXXXXXPhysical LoninationXXXXXHeightXXXXXMinghtXXXXMinghtXXX <td>Inclusion/Exclusion Criteria Check</td> <td>Х</td> <td>Х</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Inclusion/Exclusion Criteria Check	Х	Х					
Physical ConvinctionXXInternal ConversionInternal ConversionInternal ConversionXInternal ConversionXX <th< td=""><td>Medical History</td><td>Х</td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Medical History	Х						
HeightXXImageImageImageImageImageImageImageWeightXXXXXXXXChek Mal Signs'XXXXXXXECGXXXXXXXXECGXXXXXXXXLie and decitotylesXXXXXXXUre and decitotylesXXXXXXXSpatan sample for CS sar antibiotic resideance tailorgiXXXXXXSpatan sample for GS sar antibiotic resideance tailorgiXXXXXXXSpatan sample for GS sar antibiotic resideance tailorgiXXXXXXXXSpatan sample for GS sar antibiotic resideance tailorgiXX <td></td> <td>Х</td> <td>Х</td> <td>Х</td> <td>Х</td> <td>Х</td> <td>Х</td> <td>Х</td>		Х	Х	Х	Х	Х	Х	Х
WeightXXXIIIIIChek Wal Sgins*XXXXXXXEGXIIIIIIFul Bodc cantXIIIIIIUra and elschytesXIIIIIILura and elschytesXIIIIIILura and elschytesXIIIIIISultar and elschytesXIIIIIILura and elschytesXIIIIIIISultar and elschytesXIIIIIIIISultar and elschytesXIIIIXXXXXXResearch Bodd Sangle*XXIIIXX <td>Physical Examination</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Х</td>	Physical Examination							Х
Check Wal Signs* X X X X X X EGG X Full bod cound X Urea and obscholytes X Urea and obscholytes X Standar Spinor Cr S and antibiotic resistance lessing? X X X X Sputum samples for Cr S and antibiotic resistance lessing? X X X X X Sputum sample for stronge? X X X X X X Sputum sample for stronge? X X X X X X X Sputum sample for stronge? X X X X X X X Sputum sample for stronge? X X X X X X X Sputum sample for stronge? X X X X X X X Sputum sample for stronge? X X X X X X Spaced for stronge? X								
ECC X Image: Constraint of the second secon	Weight	Х						
Induction X International state X International state International state Urea and decinations X International state X International state Sputum samples for C-S and antibule resistance testings X International state X X Sputum samples for C-S and antibule resistance testings X International state X X X Sputum samples for C-S and antibule resistance testings X International state X X X Sputum samples for Stargel* International state X International state X X X Standard Spirometry X X X X X X X Quality off the forchiectasis quality X X X X X X SGRO International state X X X X X X SGRO International state X X X X X X SGRO International state X X X X X X SGRO International state X X X X X SGRO International state X X X X <td>Check Vital Signs^</td> <td>Х</td> <td>х</td> <td></td> <td></td> <td>Х</td> <td>Х</td> <td>х</td>	Check Vital Signs^	Х	х			Х	Х	х
Urea and electrolytes X X Image: Constraint of the starting of the sta	ECG	Х						
Live function tests X X X X X Sputurn samples for C-S and antibioic restance testing/ X X X X Research Blood Sample '` X X X X Sputurn samples for C-S and antibioic restance testing/ X X X X Research Blood Sample '` X X X X Sputurn sample for strange! X X X X Sputurn sample for strange! X X X X Sputurn sample for strange! X X X X Sputurn sample for for strange! X X X X Sputurn sample for testing / X X X X Questionnelse X X X X X Sputurn sample for testing / X X X X X Spectra for testing / X X X X X X Spectra for testing / X X X X X X Spectra for testing / X X X X X X Spectra for testing / X X X X X Specrive firs	Full blood count	Х						
Sputen samples for C-S and antibiolic (resistance lessing)XXXXSputen sample for Storage*XXXXXSputen sample for storage*XXXXXSputen sample for storage*XXXXXOualty of life bronchiectasis questionnaiceXXXXXOualty of life bronchiectasis questionnaiceXXXXXXSGRQXXXXXXXBHGXXXXXXXBHGXXXXXXXSopervised lifsi does of trial medicationXXXXXXSupervised lifsi does of trial medicationXXXXXXSupervised lifsi does of trial medicationXXXXXXSeley Spirometry Post trial medicationXXXXXXSeley Spirometry Fost trial medicationXXXXXXRecord Alverese EventsXXXXXXXRecord Alverese EventsXXXXXXXDispense Trial Drugs**IXXXXXXRandomisationXXXXXXXXDispense Trial Drugs**IXXXXX </td <td>Urea and electrolytes</td> <td>Х</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Urea and electrolytes	Х						
restance testing/fAAAAResearch Blood Sample*'IXIXXXStandard SpirometryXXXXXXStandard SpirometryXXXXXXXXXXXXQuetty offic brochectasisXXXXXXXXXXXGotty offic brochectasisXXXXXXXXXXXXSGRQIXXXXXXXXXXXXBHOIXXXXXXXXXXXXExacebation recordingIXXXXXXXXXXXXVial nasel swabIXXIIXXXXXXXXSpervised first dose of trial medicationXXXXIIIIISoportize Severity index and components e g MRC dyspneas soreXXXIIIIRecord Adverse FrentsIXXXXXXXXIXXIIBegens Frial Drugs**IIXXIXXXXXIIIIDegrense Frial Drugs**IIXXIXIXIXIIIIBegens Frial Drugs**IIIXIXIXIXIXIIIIBegens Frial Drugs**IIXIXIXIXIXIXIXIIIII	Liver function tests	Х						
Sputum sample for storage ⁶ NXXXXSlandard SpironelyXXXXXXSlandard SpironelyXXXXXXQuality offic bronchectusis questionnaire.XXX&X&XXSGRQXXXXXXXSGRQXXXXXXXBHQXXXXXXXExacetablon recordingIXXXXXXViral nasal swabIXXXXXXSupervised first dose of trial medicationXXIIIISafety Spironetry Post trial medicationXXIIIIBronchiectasis severity index and components e.g MRC dyspinoea scoreXXIIIRecord Adverse EvenisIXIIIIIRecord Adverse EvenisIXXXXXXRandomisationIXXXXIIDisperse Frial Drugs**IIXXXXIRandomisationIXXXXXIIDisperse Frial Drugs**IX*XXXIIDisperse Frial Drugs**X*X*XXXII </td <td></td> <td>х</td> <td></td> <td></td> <td></td> <td>х</td> <td>Х</td> <td>х</td>		х				х	Х	х
Standard SpirometryXXXXXXXQuality offic tronchicctasis questionarize &XX&X&X&XXSGRQXXXXXXXSGRQXXXXXXXBHQXXXXXXXExacerbalion recordingXXXXXXXVral nasal swabXXXXXXXSupervised first dose of trial medicationXXXXXXSafety Sprometry Post trial medicationXXXXXXBronchectasis seventy index and components e.g MRC dyspnes accoreXXXXXXRecord Adverse EventsXXXXXXXXDispense Trial Drugs**XX*XXXXXDrug Beturn And Compliance CheckXX*XXXXRandomisationX*X*XXXXDrug Beturn And Compliance CheckX*X*XXXXRandomisationX*X*XXXXXDrug Beturn And Compliance CheckX*X*X*XXXRandomisationX*X*X*X*XXXDrug Beturn And Compliance CheckX*X* <td></td> <td></td> <td>Х</td> <td></td> <td></td> <td>Х</td> <td>Х</td> <td>Х</td>			Х			Х	Х	Х
Quality of the bronchiectasis questionnaire&XX&X&X&XXSGRQXXXXXXSGRQXXXXXXBHQXXXXXXExacerbation recordingXXXXXXViral nasil swabXXXXXXSupervised first dose of trial medicationXXXXXXSupervised first dose of trial medicationXXXXXXXSupervised first dose of trial medicationXXXXXXSupervised first dose of trial medicationXXXXXXSupervised first dose of trial	Sputum sample for storage ^b							
questionnaire& Λ		Х	X			Х	Х	Х
BHQXXXXXXXExacebation recordingXXXXXXXViral nasal swabXXXXXXXSupervised first dose of trial medicationXXXXXXSafety Spirometry Post trial medicationXXXXXXBronchiectasis severity index and components e.g MRC dyspnoea scoreXXXXXXPregnancy Testing if ApplicableXXXXXXXBrandomisationXXXXXXXDispense Trial Drugs**XXXXXXXDispense Trial Drugs**XXXXXXDispense Trial Drugs**XXXXXXDispense Trial Drugs**XXXXXXDispense Trial Drugs**XXXXXXDispense Trial Drugs**XXXXXXDispense Trial Drugs**XXXXXXDispense Trial Drugs**X*X*X*XXXDispense Trial Drugs**X*X*X*X*XDispense Trial Drugs**X*X*X*X*X*Dispense Trial Drugs**X*X*X*X*X*Dispense Trial Drugs**<			Х	X&	X&	X&	Х	Х
Exacerbation recordingXXXXXXXXViral nasal swabXXXXXXXSupervised first dose of trial medicationXXXXXSafety Spirometry Post trial medicationXXXXXBronchiectasis severity index and components eg MRC dyspnes accoreXXXXXPregnancy Testing If ApplicableXXXXXXRandomisationXXXXXXDispense Trial Drugs**XXXXXXDispense Trial Drugs**XXXXXXRandomisationXXXXXXDispense Trial Drugs**XXXXXXDispense Trial Drugs**XXXXXXRandomisationXXXXXXDispense Trial Drugs**XXXXXRandomisationXXXXXXDispense Trial Drugs**X*X*XXXXRandomisationX*X*X*XXXDispense Trial Drugs**X*X*X*X*X*RandomisationX*X*X*X*XXDispense Trial Drugs**X*X*X*X*X*Dispense			Х	Х	Х	Х	Х	
Viral nasal swabXXXSupervised first dose of trial medicationXXImage: Second	BHQ						Х	
Supervised first dose of trial medicationXXImage: Constraint of trial medicationSafety Spirometry Post trial medicationXXImage: Constraint of trial medicationBronchiectasis severity index and components e.g. MRC dyspneea scoreXXImage: Constraint of trial medicationPregnancy Testing If ApplicableXXXXXRecord Adverse EventsXXXXXRandomisationXXXXXDispense Trial Drugs**XXXXXCourier drugs to participantXXXXXDispense Trial Drugs**XXXXXDispense Trial Drugs**XXXXXDispense Trial Drugs**XXXXXDispense Trial Drugs**XXXXXDrug Return And Compliance CheckXXXXXDispense Trial Drugs**X*X*X*XXDispense Trial Drugs**X*X*X*X*XDispense Trial Drugs**X*X*X*X*X*Dispense Trial Drugs**X*X*X*X*X*Dispense Trial Drugs**X*X*X*X*X*Dispense Trial Drugs**X*X*X*X*X*Dispense Trial Drugs**X*X*X*X*X*Dispense Trial Drugs**X*X*				Х	Х	Х		
LandImage: Constraint of the second seco	Viral nasal swab		Х				Х	Х
International of the second	Supervised first dose of trial medication		Х					
components e.g MRC dyspnoea scoreXXXXXXPregnary Testing If ApplicableXXXXXXXRecord Adverse EventsCXXXXXXRandomisationXXXXXXXDispense Trial Drugs**GXXXXXCourier drugs to participantGXXXXXDispense Trial Drugs**GXXXXXDispense Trial Drugs**GX°X°X°XXDispense Trial Drugs**KX°X°X°KK	Safety Spirometry Post trial medication		Х					
Record Adverse EventsXXXXXXRandomisationXXXXXXDispense Trial Drugs**MXaXaXaXaXaCourier drugs to participantMXaXaXaMMDrug Return And Compliance CheckMXXXXMRandomisationXaXaXaXaXaMDispense Trial Drugs**XaXaXaXaM	components e.g MRC dyspnoea score	x						
RandomisationXImage: Constraint of the systemXImage: Constraint of the systemXImage: Constraint of the systemXXXImage: Constraint of the systemDisperse Trial Drugs**Image: Constraint of the systemImage: Constraint of the sys		Х						
Dispense Trial Drugs**NaNaNaNaNaCourier drugs to participantImage: CheckImage: NaImage: NaImage				Х	Х	Х	Х	Х
Courier drugs to participant Image: Courier drugs to par								
Drug Return And Compliance Check M X <			Xa			Xa		
Randomisation X Image: Constraint of the second se								
Dispense Trial Drugs** X ^a X ^a X ^a X ^a			V	Х	X	Х	Х	
				Va	Va	Va		
Counce drags to participant.			Λ"			۸۳		
Drug Return And Compliance Check X X X X X						Х	Х	

Vital BE Visits V1 12-05-23







Visit 1 – Screening (approx. 2 – 3 hours)

- Establish participant identity
- Informed consent
- Medical history including concomitant medication check
- Physical examination (doctor)
- Height & weight
- Vital Signs
- ECG
- Full blood count, urea & electrolytes and liver function tests (local NHS labs)
- Serum pregnancy test, if required (local NHS labs)
- Research blood samples
- Sputum sample for *P. aeruginosa* testing (local NHS labs)
- Spirometry
- Bronchietasis severity index
- Questionnaires

- ECG and all NHS lab results to be reviewed by doctor on Delegation Log
- If found to be ineligible, all procedures except blood and sputum sample collection should be completed, if participant agreeable.
- Where an ineligible participant's medical condition or concomitant medications change sufficiently so that they are deemed potentially eligible for the trial, they may be rescreened.
 - Must receive a new copy of the PIS, be re-consented and given a new Participant ID number.
- Details of **all** participants **consented** to the trial to be recorded on the Enrolment and Randomisation Log.







Arranging next visit – timelines (inclusion criteria)

Ensure that the following timelines will be met on the day of visit 2:

- Visit must be arranged within 35 days of Visit 1
- A sputum sample that is culture or PCR positive for *P. aeruginosa* or other Gram-negative respiratory pathogens within 35 days prior to visit 2
- History of at least 3 exacerbations in the previous 12 months
- Pseudomonas aeruginosa or other Gram-negative respiratory pathogen detected in sputum or bronchoalveolar lavage on at least 1 occasion in the previous 12 months
- Ensure a negative serum pregnancy test **at screening** for women of childbearing potential



Arranging next visit – timelines (exclusion criteria)

Ensure that the following timelines will be met on the day of visit 2:

- Recent significant haemoptysis (a volume requiring clinical intervention, within the previous 4 weeks).
- Treatment with inhaled, systemic or nebulized anti-Pseudomonal antibiotics in the 28 days prior to randomization
- Treatment of an exacerbation and receiving antibiotic treatment within 4 weeks prior to randomization.
- Pregnant or lactating females.



Visit 2 Baseline/Randomisation (approx. 2 hours)

- Establish participant identity
- Confirm continued consent
- Inclusion/exclusion criteria check
- Adverse event recording
- Concomitant medication check
- Vital signs
- Urine pregnancy test, if required
- Exacerbation recording
- Sputum samples
- Eligibility confirmed by delegated doctor
- Randomisation
- IMP Dispensed
- First Dose
- Sputum samples
- Questionnaires

- All NHS lab results must be reviewed by doctor on Delegation Log
- Eligibility to be assessed once all blood and sputum results have been reviewed
- Assessment of eligibility must be carried out by doctor on Delegation Log
- Date of randomisation should be added to the Enrolment and Randomisation Log.



Trial Medication

Trial medication is given in 28 day cycles with participants taking 28 days of trial medication followed by 28 days not taking trial medication for the 12 months of the trial.

See Trial Medication Guide for mixing Aztreonam/placebo 75mg with the saline.

Nebuliser and handset

Each participant will be given an eFlow nebuliser machine and Altera nebuliser handset which must be used with the trial medication.

The nebuliser machine and handsets must only be used with the trial medication and must not be used for other inhaled medications. The trial medication must only be taken via the supplied nebuliser and handset and not with any other nebuliser machine.

The nebuliser machine will be supplied to the research team and should be given to the participant after randomisation.

A new nebuliser handset should be used for each 28-day cycle of treatment, these will be supplied along with their trial medication from pharmacy. Handsets should be disposed of at home by the participant or in clinical waste at the hospital via the research team. They should not be returned to pharmacy.

Participants must be shown how to use the nebuliser and handset during the administration of the first dose of trial medication at visit 2 see Trial Medication Guide and video "Mixing and storing your Cayston" (from 1 min 11 secs to 2 min 46 secs only)









First dose of trial medication

It is possible that participants may experience bronchospasm with the trial medication therefore participants will receive their first dose of trial medication at visit 2. Research staff could keep the empty vial from the first dose in the box for accountability purposes.

The first dose of trial medication should be given to the participant at visit 2.

After Randomisation collect the allocated trial medication from the Clinical Trial Pharmacy

Ask the participant to set up their nebuliser system as per video and trial medication guide





Participant Pack:

When randomised participants should be given the following to take away:

- Trial bag
- Trial Medication 28 days' supply, (3 packs)(first dose taken at this visit)
- Nebuliser controller unit
- Nebuliser handset
- Trial Medication Guide
- Contact Card
- Participant Appointment Sheet
- Copy of Informed Consent Form
- Questionnaires QoL-B to complete between Visits 2 and 5



Visit 3 – Month 1 (4 weeks) & Visit 4 – Month 3 (12 weeks) Telephone call

- Establish participant identity
- Confirm continued consent
- Adverse event recording
- Concomitant medication check
- Exacerbation recording
- Questionnaires



Visit 5 – Month 6 (24 weeks)

- Establish participant identity
- Confirm continued consent
- Adverse event recording
- Concomitant medication check
- Vital Signs
- Urine pregnancy test, if required
- Sputum
- Spirometry
- Exacerbation recording
- Research Blood Sample
- Return of used/unused IMP vials
- QoL-B questionnaires completed between Visit 2 -5
- Questionnaires









Visit 6 – Month 12 (48 weeks)

- Establish participant identity
- Confirm continued consent
- Adverse event recording
- Concomitant medication check
- Exacerbation recording
- Vital signs
- Urine pregnancy test, if required
- Research Blood Sample
- Sputum
- Spirometry
- Return of used/unused IMP vials
- QoL-B questionnaires completed between Visit 5 -6
- Questionnaires







Unscheduled visit (as required)

- Establish participant identity
- Confirm continued consent
- Adverse event recording
- Concomitant medication check
- Exacerbation recording
- Vital signs
- Urine pregnancy test, if required
- Research blood sample
- Sputum
- Spirometry
- Questionnaires

